TrialAnnals of the rheumatic diseases2022

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Maria C Cid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.